Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Nitroxyl Stories

2014-02-25 08:32:27

Cardioxyl now evaluating clinical safety and tolerability of improved second-generation HNO prodrug targeting acute decompensated heart failure CHAPEL HILL, N.C., Feb. 25, 2014 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today that the first cohort of patients has been dosed in a Phase I clinical trial of CXL-1427, a novel nitroxyl (HNO) prodrug optimized for clinical development as a potential treatment for acute decompensated heart failure (ADHF). The primary...

2013-11-11 08:28:50

The Article Discusses a New Study that has Found that Those Who Take the Drug have a Decreased Risk of Heart Attack and Stroke due to Increased Nitric Oxide LOS ANGELES, Nov. 11, 2013 /PRNewswire-iReach/ -- Nitro Solution, a website that offers high quality and all natural nitric oxide supplements, has just posted a new article to its website that addresses a new study that looked at the unexpected benefits of a drug called Amlodipine. (Photo:...

2013-10-28 08:29:50

CHAPEL HILL, N.C., Oct. 28, 2013 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today the publication of recent findings on the role of a novel pure nitroxyl (HNO) donor in enhancing cardiac function and hemodynamics. These findings, based upon analysis of preclinical and human clinical data from studies of CXL-1020, were published online October 9, 2013, in Circulation: Heart Failure, which is published by the American Heart Association. "Patients with acute decompensated...

2013-09-18 16:25:55

The Recently Launched Site Features an All-Natural Product Called Nitroxyl LOS ANGELES, Sept. 18, 2013 /PRNewswire-iReach/ -- Nitro Solution, a website that offers high quality and all-natural nitric oxide supplements, has just launched its brand new and user-friendly site. In addition to featuring the safe and innovative supplement called Nitroxyl, Nitro Solution is also devoted to educating its customers about nitric oxide and its impact on health and overall wellness. (Photo:...

2013-09-11 08:28:10

CHAPEL HILL, N.C., Sept. 11, 2013 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today the appointment of Shi Yin Foo, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Foo, who has broad experience in the development of cardiovascular drugs and translational medicine, is well positioned to help Cardioxyl realize the potential of its nitroxyl (HNO) technology for the treatment of patients with serious cardiovascular disease. Dr. Foo joins Cardioxyl from Novartis, where she...

2012-11-13 08:36:22

CHAPEL HILL, N.C., Nov. 13, 2012 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today that it has raised $28 million in a Series B financing led by OrbiMed Advisors. New investor Osage University Partners joined OrbiMed and returning investors New Enterprise Associates (NEA) and The Aurora Funds in the financing. Proceeds from this latest round will be used to further advance Cardioxyl's second-generation nitroxyl (HNO) donor programs for the treatment of acute and chronic heart...

2011_130_Nature_Wie_das_Treibhausgas_N2O_abgebaut_wird_72dpi
2011-08-22 20:21:28

For the First Time, Microbiologists Identified the Structure of the Bacterial Enzyme that Decomposes Nitrous Oxide and the Decomposition Mechanism Nitrous oxide (N2O) is a harmful climate gas. Its effect as a greenhouse gas is 300 times stronger than that of carbon dioxide. Nitrous oxide destroys the ozone layer. In industrial agriculture, it is generated on excessively fertilized fields when microorganisms decompose nitrate fertilizers. Decomposition of nitrous oxide frequently is...

2011-04-04 12:45:00

NEW ORLEANS and CHAPEL HILL, N.C., April 4, 2011 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today that it is presenting two abstracts from studies of its lead clinical candidate, CXL-1020, at the American College of Cardiology's (ACC) 60th Annual Scientific Session & Expo in New Orleans, Louisiana. Preclinical results highlighted in the first abstract demonstrate CXL-1020's ability to work independently from other heart failure therapies, furthering important insights...

2010-08-26 07:30:00

CHAPEL HILL, N.C., Aug. 26 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutic agents for the treatment of cardiovascular disease, today announced that it has initiated a dose-defining Phase IIa trial of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure (ADHF). ADHF is the leading diagnosis for patients at the time of discharge from U.S. hospitals and the most common cause of...

cd3bd565e59714471566f407980c7a0e1
2009-07-06 11:25:00

Wake Forest University scientists have developed a new research tool in the pursuit of heart medications based on the compound nitroxyl by identifying unique chemical markers for its presence in biological systems.Nitroxyl, a cousin to the blood-vessel relaxing compound nitric oxide, has been shown in studies to strengthen canine heart beats, but research into its potential benefits for humans has been slowed by a lack of specific detection methods."I think this is a very powerful tool to...